• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2021 年出现具有独特遗传特征的新一轮 COVID-19——当前的全球形势及未来展望。

A New Wave of COVID-19 in 2021 with Unique Genetic Characters - Present Global Scenario and Beholding Onwards.

机构信息

Department of Biochemistry, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh-462020, India.

Independent Researcher. Bhopal, Madhya Pradesh-462020, India.

出版信息

Infect Disord Drug Targets. 2022;22(6):e010422202932. doi: 10.2174/1871526522666220401101818.

DOI:10.2174/1871526522666220401101818
PMID:35366784
Abstract

After the first report of a coronavirus-associated pneumonia outbreak in December 2019, the virus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) that causes the infection/disease (COVID-19) has developed into a pandemic, with >100 million people infected in over 210 countries along with two million people deceased from COVID-19 till today. Coronaviruses are positivestranded RNA viruses having restricted RNA polymerase proofreading ability thus it is very genetically susceptible to mutation. The evolution of SARS-CoV-2 from a single-point zoonotic introduction in Wuhan in November or December 2019 was widely expected, and viral sequence surveillance was developed as a result. When the first sequence of SARS-CoV-2 was released, a race to develop vaccines started, and several vaccines are now used worldwide. Independent SARS-CoV-2 lineages have recently been identified in the UK (B.1.1.7), Brazil (P.1), South Africa (B.1.351), and India (B.1.617). The recent appearance of several SARS-CoV-2 variant strains has shattered faith in the modern generation of vaccines' ability to provide enduring defense against infection. The risk of escaping natural and induced immunity has encouraged an urgency to comprehend the implications of these improvements, as well as a drive to develop new approaches to combat SARS-CoV-2 variants.

摘要

自 2019 年 12 月首次报告冠状病毒相关肺炎疫情以来,导致感染/疾病(COVID-19)的病毒 SARS-CoV-2(严重急性呼吸系统综合征冠状病毒 2)已发展成为一种大流行病,已有超过 1 亿人在 210 多个国家感染,并有 200 万人死于 COVID-19。冠状病毒是正链 RNA 病毒,其 RNA 聚合酶校对能力有限,因此非常容易发生突变。人们普遍预计,SARS-CoV-2 会从 2019 年 11 月或 12 月在武汉的单点人畜共患传播中进化而来,因此开发了病毒序列监测。当第一个 SARS-CoV-2 序列发布时,一场疫苗研发竞赛就开始了,现在全球范围内使用了几种疫苗。最近在英国(B.1.1.7)、巴西(P.1)、南非(B.1.351)和印度(B.1.617)发现了独立的 SARS-CoV-2 谱系。最近出现的几种 SARS-CoV-2 变异株打破了人们对现代一代疫苗能够提供持久抗感染能力的信心。逃避自然和诱导免疫的风险促使人们迫切需要了解这些改进的意义,并推动开发新的方法来对抗 SARS-CoV-2 变异株。

相似文献

1
A New Wave of COVID-19 in 2021 with Unique Genetic Characters - Present Global Scenario and Beholding Onwards.2021 年出现具有独特遗传特征的新一轮 COVID-19——当前的全球形势及未来展望。
Infect Disord Drug Targets. 2022;22(6):e010422202932. doi: 10.2174/1871526522666220401101818.
2
Third Wave of the COVID-19 Pandemic: Prominence of Initial Public Health Interference.第三波 COVID-19 大流行:最初公共卫生干预措施的突出地位。
Infect Disord Drug Targets. 2022;22(4):e080222200919. doi: 10.2174/1871526522666220208115101.
3
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.新冠病毒-19(Sars-Cov-2)的英国变体不应造成疫苗问题。
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.
4
SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus.SARS-CoV-2 将不断扫荡其踪迹:一种含有 CpG 基序的“套索”疫苗,针对多面病毒。
Inflamm Res. 2020 Sep;69(9):801-812. doi: 10.1007/s00011-020-01377-3. Epub 2020 Jul 12.
5
COVID-19: A Worldwide, Zoonotic, Pandemic Outbreak.新型冠状病毒肺炎:一场全球性的人畜共患病大流行疫情。
Altern Ther Health Med. 2020 Aug;26(S2):56-64.
6
The novel zoonotic COVID-19 pandemic: An expected global health concern.新型人畜共患的新冠疫情:一个意料之中的全球卫生问题。
J Infect Dev Ctries. 2020 Mar 31;14(3):254-264. doi: 10.3855/jidc.12671.
7
Molecular evolution of SARS-CoV-2 from December 2019 to August 2022.SARS-CoV-2 的分子进化:2019 年 12 月至 2022 年 8 月。
J Med Virol. 2023 Jan;95(1):e28366. doi: 10.1002/jmv.28366.
8
COVID-19: from the structure and replication cycle of SARS-CoV-2 to its disease symptoms and treatment.新型冠状病毒肺炎:从 SARS-CoV-2 的结构和复制周期到其疾病症状和治疗方法。
J Physiol Pharmacol. 2021 Aug;72(4). doi: 10.26402/jpp.2021.4.01. Epub 2021 Dec 31.
9
The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status.新型严重急性呼吸系统综合症冠状病毒 2(SARS-CoV-2)的爆发:当前全球状况综述。
J Infect Public Health. 2020 Nov;13(11):1601-1610. doi: 10.1016/j.jiph.2020.07.011. Epub 2020 Aug 4.
10
SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines.严重急性呼吸综合征冠状病毒2:既往冠状病毒、免疫反应及疫苗研发
Bol Med Hosp Infant Mex. 2020;77(5):252-261. doi: 10.24875/BMHIM.20000191.

引用本文的文献

1
A New-fangled COVID-19 Variant, Eris, Might be the One to Lookout in 2023 or far from Over.一种新型的 COVID-19 变体,Eris,可能是 2023 年需要关注的对象,亦或尚未结束。
Infect Disord Drug Targets. 2024;24(6):e220124225916. doi: 10.2174/0118715265276833240105110046.
2
COVID-19 mortality in Brazil, 2020-21: consequences of the pandemic inadequate management.2020 - 2021年巴西的新冠病毒疾病死亡率:疫情管理不善的后果
Arch Public Health. 2022 Dec 19;80(1):255. doi: 10.1186/s13690-022-01012-z.